Lupus erythematosus - 红斑狼疮
relevance score : -100.0%
ReferencesCutaneous lupus erythematosus (CLE) 的识别和分类给诊断带来挑战，需要将其与皮肤受累的 systemic lupus erythematosus 区分开来。最新研究揭示了 CLE 的遗传、环境和免疫因素。药物诱导已成为 CLE 最重要的触发因素之一。治疗包括局部和全身方案，其中有前景的生物制剂如 belimumab、rituximab、ustekinumab、anifrolumab 和 BIIB059，已在临床试验中证明疗效。
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) 涵盖各种皮肤问题，其中一些可能与更广泛的健康问题有关。它分为不同的类型，例如 acute CLE (ACLE)、sub‑acute CLE (SCLE) 和 chronic CLE (CCLE)。CCLE 包括 discoid lupus erythematosus (DLE)、LE profundus (LEP)、chilblain cutaneous lupus 和 lupus tumidus。
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus 是一组可影响身体不同部位的自身免疫性疾病。有些类型，如 systemic lupus erythematosus (SLE)，会累及多个器官；而另一些类型，如 cutaneous lupus erythematosus (CLE)，主要表现为皮肤受累。我们通过临床表现、组织学检查和血液检查对 CLE 的不同亚型进行分类，但患者之间差异很大。皮肤症状常因日晒、吸烟或使用某些药物等因素诱发。
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
红斑狼疮 (lupus erythematosus) 的病因尚不清楚。在同卵双胞胎中，如果一方受到影响，另一方有 24% 的概率也会受到影响。女性性激素、阳光、吸烟、维生素 D 缺乏和某些感染也被认为会增加患病风险。
治疗方法可能包括非甾体抗炎药、皮质类固醇、免疫抑制剂、羟氯喹和甲氨蝶呤。尽管皮质类固醇有效，但长期使用会产生副作用。